Used in antibody-drug conjugates (ADCs) for targeted cancer therapy. The compound links monoclonal antibodies to potent cytotoxic agents, enabling selective delivery of the drug to tumor cells. Upon binding to the target antigen on cancer cells, the ADC is internalized and the linker-payload is released, triggering cell death. This construct improves therapeutic efficacy while minimizing damage to healthy tissues. Commonly applied in research and development of oncology treatments, particularly for solid tumors and hematological malignancies.